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background: Left ventricle (LV) remodeling after anterior wall myocardial infarction (AWMI) leads to increased LV volumes, myocardial stress, and 
ultimately heart failure (HF). Treatment options are limited for these high-risk HF patients. A pooled analysis of the first 100 patients treated with 1 
year follow-up using the Parachute device will be available for presentation at ACC 2014.
aims: To confirm the acute safety and acute and long-term efficacy of PVR using an expanded range of Parachute TM device sizes in patients with 
ischemic HF with prior AWMI.
Methods: Approximately 100 patients with NYHA class II-IV HF secondary to AWMI, with akinetic or dyskinetic wall motion abnormality, LV ejection 
fraction < 40%, and have been fully revascularized were enrolled into this non-randomized trial data set from the United States and European. Major 
endpoints were death and repeat hospitalization.
results: As of December 21, 2012, 106 patients were treated. 1 year FU data will be completed by February 2014. Six month results of this cohort 
were presented at EuroPCR 2013 by Dr. Martyn Thomas. The 6M summary was a 95% treatment success, 89% of patients maintained or improved 
functional status measured by NYHA, and 17.9% death and HF hospitalization rate.
conclusions: This pooled analysis of PVR using an expanded range of Parachute device sizes in patients with ischemic HF and prior AWMI is 
anticipated to confirm the safety and longer term efficacy of this approach to treating HF.
